BUSINESS● LOW3h ago · Sep 15, 2026, 4:50 PM
Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy
Seeking Alpha Tech · global
Scholar Rock received a downgrade from Barclays, despite the recent FDA approval of its SMA therapy, indicating a divergence in market perception and regulatory success.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS15m agoAmericans' incomes rose and poverty fell in 2025, Census Bureau saysCNBCBUSINESS21m agoDine Brands expands its dual Applebee's-IHOP location concept amid strong demandSeeking Alpha Tech